APG Asset Management N.V. Cuts Stock Holdings in DexCom, Inc. $DXCM

APG Asset Management N.V. decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 227,347 shares of the medical device company’s stock after selling 16,235 shares during the quarter. APG Asset Management N.V.’s holdings in DexCom were worth $14,373,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Golden State Wealth Management LLC grew its holdings in shares of DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the last quarter. Private Trust Co. NA lifted its position in DexCom by 99.4% during the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 335 shares during the period. Farther Finance Advisors LLC lifted its position in DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company’s stock valued at $209,000 after purchasing an additional 702 shares during the period. Dynamic Advisor Solutions LLC lifted its position in DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company’s stock valued at $357,000 after purchasing an additional 1,333 shares during the period. Finally, Stonebridge Financial Group LLC lifted its position in DexCom by 944.5% during the first quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company’s stock valued at $220,000 after purchasing an additional 2,909 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Argus assumed coverage on shares of DexCom in a research report on Thursday. They issued a “buy” rating and a $100.00 price target on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $106.00 price target on shares of DexCom in a research report on Friday, August 1st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.89.

DexCom Stock Up 2.0%

Shares of DXCM stock opened at $82.26 on Monday. The company has a market capitalization of $32.26 billion, a price-to-earnings ratio of 57.13, a PEG ratio of 1.72 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The company’s fifty day moving average price is $82.81 and its 200-day moving average price is $79.77. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the company posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the firm’s stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares in the company, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at $7,555,449.58. The trade was a 0.53% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,906 shares of company stock valued at $1,832,451. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.